Cadaveric cardiosphere-derived cells can maintain regenerative capacity and improve the heart function of cardiomyopathy

Sun, Yong; Chen, Di; Ming, Tan; Kang, Kai; Zhang, Maomao; Jin, Xiangyuan; Leng, Xiaoping; Cao, Rui; Liu, Xianglan; Yu, Bo; Wu, Jiarui

doi:10.1080/15384101.2016.1160973

Cited by 8 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiosphere-derived cells transplantation elicits cardioprotection function that has been elucidated in different animal models with MI injury ( 9 , 42 , 43 ). We showed that MI mice exhibited severe cardiac dysfunction with cardiomyocyte necrosis, fibrosis, and thinning of the ventricular wall, while iECDCs transplanted hearts displayed better contractility and reduced fibrosis.…”

Section: Discussionmentioning

confidence: 99%

“…CDCs possess a multipotential differentiation ability in vitro , mainly for cardiomyocytes, endothelial cells, and smooth muscle cells ( 1 , 6 ). In the recent years, CDCs transplantation and paracrine exosomes emerged as a promising therapeutic option for many cardiac diseases including myocardial infarction (MI) ( 7 , 8 ), dilated cardiomyopathy ( 9 , 10 ), and dystrophic cardiomyopathy ( 11 , 12 ). Many clinical trials have proved the safety and efficiency of autologous and allogeneic CDCs therapy such as the CArdiosphere-Derived aUtologous stem CElls to Reverse ventricUlar dySfunction (CADUCEUS) trial ( 13 ), the AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA) trial ( 14 ), the ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial ( 15 ), and the Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells (DYNAMIC) trial ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epicardium-Derived Tbx18+ CDCs Transplantation Improve Heart Function in Infarcted Mice

Guo

Geng

Qin

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiosphere-derived cells (CDCs) constitute a cardiac stem cell pool, a promising therapeutics in treating myocardial infarction (MI). However, the cell source of CDCs remains unclear. In this study, we isolated CDCs directly from adult mouse heart epicardium named primary epicardium-derived CDCs (pECDCs), which showed a different expression profile compared with primary epicardial cells (pEpiCs). Interestingly, pECDCs highly expressed T-box transcription factor 18 (Tbx18) and showed multipotent differentiation ability in vitro. Human telomerase reverse transcriptase (hTERT) transduction could inhibit aging-induced pECDCs apoptosis and differentiation, thus keeping a better proliferation capacity. Furthermore, immortalized epicardium CDCs (iECDCs) transplantation extensively promote cardiogenesis in the infracted mouse heart. This study demonstrated epicardium-derived CDCs that may derive from Tbx18+ EpiCs, which possess the therapeutic potential to be applied to cardiac repair and regeneration and suggest a new kind of CDCs with identified origination that may be followed in the developing and injured heart.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Epicardium-Derived Tbx18+ CDCs Transplantation Improve Heart Function in Infarcted Mice

Guo

Geng

Qin

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Recently, researchers have begun investigating the functionality of intracellular process such as mitochondrial ATP production in relation to postmortem time (Barksdale et al , 2010); as well as the viability of cadaver tissue for use in transplantation and regenerative medicine (O’Driscoll et al , 1999; Shikh Alsook et al , 2015). The results of these studies suggest that cadaver tissues may remain viable anywhere from 24-h postmortem (Sun et al , 2016, Káš et al , 1969) to up to 17 days (Latil et al , 2012). To our knowledge only one other study has been conducted on wildlife models (Guinea pigs; Kas et al 1969) to investigate the potential use of tissues collected many hours after death for animal physiological studies.…”

Section: Introductionmentioning

confidence: 93%

Valuable carcasses: postmortem preservation of fatty acid composition in heart tissue

Currie

Mène-Saffrané

Fasel

2019

Conservation Physiology

View full text Add to dashboard Cite

show abstract

“…18 While percutaneous coronary intervention is suggested to have limited efficacy after the 90-minute door-to-balloon time, CDCs administered within the first 4 weeks following an ischemic event were shown to reduce the amount of fibrotic scar tissue by up to 42% in the first 12 months after MI. [18][19][20] Moreover, CDCs have also been suggested to have benefits in nonischemic dilated cardiomyopathy. 21 While the use of CDCs in HFpEF has not been as extensively studied, 1 animal model has suggested that CDCs might constitute the first effective treatment for HFpEF.…”

Section: Cardiosphere-derived Cellsmentioning

confidence: 99%

Stem Cell Therapies and Treatment Advances for Heart Failure with Preserved Ejection Fraction

Soni

Ferrell

Wikholm

et al. 2020

Georgetown Medical Review

View full text Add to dashboard Cite

Heart failure with preserved ejection fraction (HFpEF) is characterized by a left ventricular ejection fraction of 50% or greater. While heart failure with reduced ejection fraction (HFrEF) is well-characterized and has numerous treatment options, HFpEF remains poorly understood. HFpEF has long been termed diastolic dysfunction, because it was thought that fibrosis and impaired relaxation of the left ventricle could alone explain the underlying pathophysiology. However, recent research has identified additional mechanisms that influence HFpEF, specifically metabolic disorders and proinflammatory conditions. Despite this recent progress in elucidating the pathophysiology, there are still no approved treatment options that increase survival in patients with HFpEF. In the context of limited pharmacological options, stem cell therapy and cardiac biomarkers have emerged as potential breakthroughs in the treatment of HFpEF, but there has not yet been a review of their potential. This review evaluates the potential of cardiosphere-derived cells (CDCs), mesenchymal stromal cells (MSCs), and endothelial progenitor cells (EPCs) in the treatment of HFpEF. CDCs have shown promise, with a placebo-controlled animal trial demonstrating an increase in survival and a marked improvement in left ventricular end diastolic filling among the group treated with intracoronary infusion of CDCs. Additionally, with the newfound understanding of HFpEF pathophysiology, studies have also investigated the role MSCs and EPCs play in the inflammation associated with HFpEF, as well as the potential benefit these stem cells would bring to the treatment of HFpEF. While clinical trials are needed to confirm the safety and efficacy of these therapies, we offer insight into their potential, as well as a comprehensive summary of the pertinent clinical studies that are currently in progress. Embase, Ovid Medline, and PubMed were used to search all relevant literature for this review.

show abstract

Cadaveric cardiosphere-derived cells can maintain regenerative capacity and improve the heart function of cardiomyopathy

Cited by 8 publications

References 29 publications

Epicardium-Derived Tbx18+ CDCs Transplantation Improve Heart Function in Infarcted Mice

Epicardium-Derived Tbx18+ CDCs Transplantation Improve Heart Function in Infarcted Mice

Valuable carcasses: postmortem preservation of fatty acid composition in heart tissue

Stem Cell Therapies and Treatment Advances for Heart Failure with Preserved Ejection Fraction

Contact Info

Product

Resources

About